发明名称 Ribavirin-pegylated interferon alfa HCV combination therapy
摘要 A method for treating patients having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b or -2a for a time, i.e., at least about twenty-four weeks, sufficient to eradicate detectable HCV-RNA by the end of the treatment time period and to maintain no detectable HCV-RNA for at least 12 weeks after the end of the treatment time period is disclosed.
申请公布号 US2002127203(A1) 申请公布日期 2002.09.12
申请号 US20010981215 申请日期 2001.10.16
申请人 ALBRECHT JANICE K. 发明人 ALBRECHT JANICE K.
分类号 A61K31/7056;A61K38/21;A61K45/06;A61P1/16;A61P31/12;A61P31/20;(IPC1-7):A61K38/21 主分类号 A61K31/7056
代理机构 代理人
主权项
地址